Answers are grounded in this paper and cite their sources.
Microcrystal electron diffraction can determine crystal structures from pharmaceutical powders, but its performance across a diverse set of routine-origin solid forms from one highly polymorphic compound has not been systematically evaluated. We evaluated ten acalabrutinib forms selected from more than thirty identified forms and spanning anhydrates, hydrates, and solvates. Samples came from routine screening, preparation, or scale-up without purpose-grown single crystals or morphology optimization; selection was independent of apparent crystallinity, morphology, and anticipated diffraction quality. Electron diffraction determined crystal structures from all ten crystalline powder samples. Nine corresponded to selected forms, while one yielded a different form following solid-form conversion. Mother-liquor preservation combined with cryogenic preparation most consistently enabled determination of labile hydrate and solvate structures. Integration with conventional characterization detected conversions and resolved ambiguous solvent and water contents. Here, we establish a systematic single-compound benchmark supporting direct crystal-structure determination from diverse pharmaceutical crystalline powders in routine solid-form workflows.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: